Brivanib

Across CCLE and GDSC cell-line panels, response to Brivanib is significantly associated with the pathway activity of multiple pathways, with PANCREAS cell lines showing a particularly strong set of associations.

The most reproducible Brivanib response-associated pathways across cancer lineages are Response to topologically incorrect protein, 'de novo' AMP biosynthetic process, and Symbiont entry into host, each associated with drug response in up to 11 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The scatter plot shows the strongest observed association, Brivanib response versus Response to topologically incorrect protein pathway activity in PANCREAS (Pearson r = -0.41).

Pathway activity biomarkers of Brivanib response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner pathway	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
PANCREAS	Response to topologically incorrect protein →	-0.082	-0.387	.001	.004	3	11
BREAST	'de novo' AMP biosynthetic process →	+0.115	+0.485	<.001	.004	3	11
LUNG_NSCLC_LUSC	Symbiont entry into host →	-0.145	-0.512	.003	.015	3	11
LUNG_NSCLC_LUSC	Symbiont entry into host cell →	-0.145	-0.512	.003	.015	3	11
KIDNEY	Response to unfolded protein →	-0.081	-0.566	.008	.018	3	11
PANCREAS	Endoplasmic reticulum to cytosol transport →	-0.160	-0.384	.002	.006	3	10

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Brivanib response vs Response to topologically incorrect protein — PANCREAS

Explore this scatter interactively →